CEL-SCI Corporation announced the pricing of a best-efforts public offering of 1,111,200 shares of its common stock at $9.00 per share.
The total gross proceeds from the offering are expected to be approximately $10 million.
The offering is set to close on August 29, 2025, pending standard closing conditions.
Public Offering Details
1,111,200 shares of common stock priced at $9.00 per share, with expected proceeds of $10 million.
Use of Proceeds
Funding continued development of Multikine, general corporate purposes, and working capital.
Sole Placement Agent
ThinkEquity is acting as the sole placement agent for the offering.
- The offering aims to support the development of Multikine and boost the company's working capital.
- CEL-SCI's focus on cancer immunotherapy and boosting patients' immune systems reflects a unique approach in the biotech sector.
CEL-SCI's pricing of the public offering and planned use of proceeds underscore the company's commitment to advancing cancer immunotherapy research.